Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| April 2, 2018 | $0.42 | 2018-03-28 | 2018-03-29 |
| January 2, 2018 | $0.36 | 2017-12-28 | 2017-12-29 |
| October 2, 2017 | $0.24 | 2017-09-28 | 2017-09-29 |
Dividends Summary
- Consistent Payer: has rewarded shareholders with 3 dividend payments over the past 1 years.
- Total Returned Value: Investors who held AMLX shares during this period received a total of $1.02 per share in dividend income.
- Latest Payout: The most recent dividend of $0.42/share was paid 3029 days ago, on April 2, 2018.
- Yield & Schedule: AMLX currently pays dividends quarterly with an annual yield of 5.72%.
- Dividend Growth: Since 2017, the dividend payout has grown by 74.3%, from $0.24 to $0.42.
Company News
The global ALS therapeutics market is valued at USD 812 million in 2024 and is projected to reach USD 1,964 million by 2035, growing at an 11.5% CAGR. Growth is driven by innovations in genetic therapies, gene-silencing technologies, improved diagnostics, and increased disease awareness. Key players include Biogen, Ionis Pharmaceuticals, Amylyx P...
Antisense oligonucleotide (ASO) therapeutics are emerging as a promising treatment approach for rare genetic and neuromuscular disorders, with over 70 pharmaceutical companies actively developing 90+ pipeline therapeutics targeting specific genetic mechanisms.
Law firm investigating potential claims against Amylyx Pharmaceuticals regarding allegedly misleading statements about Relyvrio drug launch and patient demand during November 2022 to November 2023 period.
Law firm investigating potential claims against Amylyx Pharmaceuticals regarding allegedly misleading statements about Relyvrio drug launch and patient demand during November 2022-2023.
Amylyx Pharmaceuticals' stock rose over 10% this week after the company reported positive results from a phase 2 clinical trial of its drug AMX0035 for the rare genetic disorder Wolfram Syndrome. The treatment was well-tolerated and showed sustained improvement in pancreatic function, leading the company to plan discussions with the FDA about adv...
